LQDA Liquidia Corp
FY2025 10-K
Liquidia Corp (LQDA) filed its fiscal year 2025 10-K annual report with the SEC on Mar 5, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of inhaled treprostinil therapies for PAH and PH-ILD leveraging proprietary PRINT particle engineering technology
- • New product launch: FDA approved and commercialized YUTREPIA inhalation powder in May-June 2025, designed for higher dosing and improved lung delivery
Management Discussion & Analysis
- • Revenue $158.3M in 2025 vs $14.0M in 2024; product sales $148.3M from YUTREPIA launches, service revenue down 28% to $10.0M
- • Operating loss improved to $(51.4)M in 2025 vs $(121.3)M in 2024; SG&A rose 93% to $157.2M, R&D decreased 18% to $39.3M
Risk Factors
- • Cybersecurity risk with potential material disruption of product development programs and financial losses due to IT system failures or data breaches
- • Board Audit Committee oversight of cybersecurity risks with regular management reporting on security controls and incident response effectiveness
Financial SummaryXBRL
Revenue
$158M
Net Income
-$69M
Operating Margin
-32.5%
Net Margin
-43.5%
ROE
-154.0%
Total Assets
$328M
EPS (Diluted)
$-0.80
Operating Cash Flow
-$36M
Source: XBRL data from Liquidia Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Liquidia Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.